Central to the study is the trimeric glycoprotein of the Ravn virus (RAVV), a close relative of Marburgvirus, which facilitates viral entry into host cells by engaging the cellular Niemann-Pick C1 (NPC1) receptor. The structure of the RAVV GP-ΔM (a truncated glycoprotein) complexed with Nanosota-MB1 revealed that three nanobody molecules bind symmetrically to the trimer, each targeting a receptor-binding site. This precise engagement underscores the nanobody’s ability to firmly occlude the viral receptor interface.

Nanobodies are unique single-domain antibodies derived from camelids that consist of three complementarity-determining regions (CDRs) and four framework regions. The study identifies CDR2 and CDR3 of Nanosota-MB1 as the primary mediators of interaction with the RBS. Notably, CDR2 prominently inserts into a hydrophobic cavity within the RBS, using residues phenylalanine at position 58 (Phe58) and isoleucine at position 59 (Ile59). These residues establish strong hydrophobic contacts with key amino acids of the viral glycoprotein, including tryptophan 70 (Trp70), phenylalanine 72 (Phe72), and methionine 154 (Met154).

Fascinatingly, this binding posture mirrors that of the host receptor NPC1’s loop 2, which inserts into the same hydrophobic pocket during viral attachment. NPC1’s phenylalanines 503 and 504 (Phe503 and Phe504) interact with the RBS in a manner that the nanobody elegantly replicates. This molecular mimicry underpins the nanobody’s high binding affinity and illustrates a remarkable evolutionary convergence designed to obstruct receptor access directly.

To substantiate these structural observations, the researchers employed surface plasmon resonance (SPR) assays that demonstrated competitive binding between NPC1-C and Nanosota-MB1 to the RAVV GPcl, a cleaved form of the glycoprotein necessary for receptor interaction. When Nanosota-MB1 was bound first, subsequent addition of NPC1-C failed to engage the glycoprotein, confirming that the nanobody effectively competes for the receptor-binding site.

Complementing the binding studies, pseudovirus neutralization assays utilizing retroviruses bearing the full-length MBV glycoproteins showed that Fc-tagged Nanosota-MB1 exhibited potent neutralizing activity. This was evident across pseudoviruses derived from multiple Marburgvirus strains—including Ravn virus (RAVV), and two Marburg virus strains (Musoke and Angola). The inhibition was quantitatively assessed, with nanobody concentrations measured to establish half-maximal inhibitory concentration (IC50) values, thereby confirming its promise as a broad-spectrum antiviral agent.

This research offers a vivid molecular blueprint for designing nanobody-based therapeutics that exploit receptor mimicry to abrogate viral entry. The structural mimicry versus NPC1 receptor is particularly notable because it sheds light on viral vulnerability points that can be therapeutically targeted. Such insights are invaluable given the high fatality rates and limited treatment options associated with Marburgvirus infections.

The implications of this study extend into vaccine design, antiviral drug development, and therapeutic antibody engineering. By understanding the precise molecular interactions between viral glycoproteins and neutralizing agents, scientists can rationally design inhibitors that either prevent receptor binding or destabilize viral structure. Specifically, Nanosota-MB1 exemplifies how synthetic antibodies can be engineered to exploit naturally evolved receptor engagement mechanisms, introducing a novel paradigm in antiviral strategies.

Moreover, the crystallographic resolution achieved in the study reveals minute but critical details of hydrophobic pockets and residue-residue contacts that were previously uncharacterized. Such atomic-level insights empower the computational design of even more effective nanobody variants or small molecules that could bind the viral glycoprotein’s RBS.

Given the high mutation rates frequently observed in filoviruses, the use of structurally robust nanobodies that mimic conserved receptor contacts offers a promising route to circumvent viral escape mutations. This study provides foundational knowledge for such endeavors by highlighting conserved residues that are essential for receptor binding and thus less likely to mutate without compromising viral fitness.

In summary, the work of Ye et al. represents a significant advance in our understanding of Marburgvirus entry and neutralization. By integrating cryo-electron microscopy, biochemical assays, and neutralization experiments, the research delineates how nanobody therapy can be tailored for effective viral inhibition. This innovative approach holds the potential to deliver new countermeasures against one of the most lethal viral pathogens known to humankind.

As the world continues to grapple with emerging viral threats, these findings are a beacon of hope—offering not only a deeper mechanistic insight into viral-host interactions but also a tangible pathway toward next-generation antivirals. The structural sophistication harnessed in Nanosota-MB1 provides a template for the rational design of nanobody therapeutics with broad applications beyond Marburgvirus, potentially extending to other filoviruses and enveloped viruses.

Future research will undoubtedly build upon this work by exploring the in vivo efficacy, pharmacokinetics, and potential synergy of such nanobodies with existing antiviral treatments. Ultimately, this study lays the critical groundwork for translating structural biology into lifesaving medical interventions against Marburgvirus and related pathogens.

Subject of Research: Structural and biochemical characterization of the Marburgvirus glycoprotein and its neutralization by a nanobody mimicking the NPC1 receptor.

Article Title: Structures of Marburgvirus glycoprotein and its complex with NPC1 receptor.

Article References:
Ye, G., Bu, F., Turner-Hubbard, H. et al. Structures of Marburgvirus glycoprotein and its complex with NPC1 receptor. Nature (2026). https://doi.org/10.1038/s41586-026-10240-0

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41586-026-10240-0

SARS-CoV-2, the virus responsible for COVID-19, exploits the angiotensin-converting enzyme 2 (ACE2) receptor on human cells as its primary gateway for infection. The viral spike protein attaches with high affinity to ACE2, facilitating viral entry and subsequent replication. Consequently, interrupting this interaction has been a critical target for antiviral strategies. Traditional methods have focused extensively on targeting the virus itself—neutralizing antibodies aimed at the spike protein or vaccines eliciting immune responses. However, this new study pivots to the host receptor, ACE2, as a therapeutic target, heralding a novel approach in antiviral defense.

Central to this research is the employment of a camelid-derived antibody that exhibits unique properties making it especially suitable for therapeutic use. Camelid antibodies, derived from species like llamas and alpacas, are characterized by their single-domain structure, known as nanobodies. These nanobodies possess remarkable stability and the capability to bind epitopes that are typically inaccessible to conventional antibodies. This allows for high-affinity binding to protein targets such as ACE2, potentially blocking the virus’s ability to dock and initiate infection.

The team engineered a camelid antibody that selectively binds to the ACE2 receptor, effectively sterically hindering the SARS-CoV-2 spike protein from attaching to the receptor’s binding interface. This interference was meticulously validated through in vitro assays demonstrating a significant reduction of viral binding and entry into cultured human cells expressing ACE2. The scientific rigor and precision in designing this antibody underscores the potential of nanobody-based therapeutics in clinical applications against viral pathogens.

Importantly, the efficacy of the camelid antibody was not limited to cell culture experiments. The authors extended their investigations into robust animal models to assess in vivo protective effects. Administration of the nanobody in a murine model expressing human ACE2 conferred substantial protection against SARS-CoV-2 challenge. Mice treated with the antibody showed markedly diminished viral loads in lung tissues and reduced pathological manifestations compared to untreated controls. These findings are a crucial proof-of-concept demonstrating that targeting the host receptor directly can be both safe and effective.

Furthermore, the antibody’s ability to localize to the respiratory tract—a primary site of viral replication—enhanced its protective capacity. Intranasal delivery of the nanobody enabled direct access to the mucosal surfaces where the virus initiates infection, ensuring high local concentrations and rapid receptor occupancy. This modality presents an attractive advantage for clinical deployment, potentially offering a prophylactic tool that can be easily administered to at-risk populations or healthcare workers.

From a mechanistic standpoint, the study sheds light on the structural dynamics of the ACE2-nanobody interaction. Cryo-electron microscopy data revealed the precise binding epitopes and conformational changes induced by the nanobody, providing a detailed molecular framework that rationalizes the observed functional blockade of SARS-CoV-2 binding. This structural insight is invaluable for guiding further optimization and engineering of receptor-targeting biologics.

The specificity of the camelid antibody towards human ACE2 is a pivotal aspect, minimizing off-target effects and adverse outcomes by avoiding interactions with other proteins. Additionally, the nanobody’s small size and simple structure offer advantages in manufacturability, stability, and tissue penetration, critical factors for therapeutic development. The production scalability of camelid antibodies further adds to their appeal in responding to global health emergencies.

Notably, this research addresses lingering concerns about potential interference with ACE2’s physiological functions. ACE2 is a key enzyme in the renin-angiotensin system, implicated in cardiovascular and pulmonary homeostasis. The antibody’s binding site was carefully selected to circumvent enzymatic inhibition, preserving ACE2’s beneficial roles while blocking viral engagement. This nuanced approach balances antiviral efficacy with safety, a critical consideration often overlooked in receptor-targeted therapies.

The implications of this research extend beyond SARS-CoV-2, as the ACE2 receptor is utilized by multiple coronaviruses and related pathogens. This positions the camelid antibody as a versatile platform for broad-spectrum antiviral strategies, potentially providing cross-protective benefits against future emerging coronaviruses. Such preparedness is paramount in a world where zoonotic spillovers pose ongoing threats to global health security.

Moreover, the study’s findings invite further exploration into combination therapies. By pairing receptor-targeting nanobodies with conventional antibody cocktails or antiviral drugs, synergistic effects could be achieved, enhancing the breadth and durability of antiviral protection. This multimodal approach could be indispensable in combating viral variants exhibiting enhanced immune escape or resistance.

The work also exemplifies the innovative convergence of structural biology, immunology, and virology in rapid therapeutic development. Employing state-of-the-art biophysical techniques alongside rigorous in vivo experiments accelerated the translation of molecular insights into tangible therapeutic candidates. This integrated framework serves as a model for addressing future infectious disease challenges with unprecedented speed and precision.

As the COVID-19 pandemic persists with new variants emerging, the need for alternative therapeutics remains acute. The camelid antibody targeting ACE2 adds a potent weapon to the antiviral arsenal, complementing vaccines and antiviral drugs. Its promise lies not only in treatment but also in potential prophylaxis, particularly for individuals with compromised immunity who may not respond adequately to vaccination.

Looking ahead, clinical trials will be critical to ascertain the safety, pharmacokinetics, and efficacy of this nanobody in humans. The encouraging preclinical data pave the way for such translational efforts, fueling hope for an additional layer of protection against SARS-CoV-2. With further refinement and validation, this strategy could revolutionize how receptor-targeted interventions are deployed against respiratory viruses.

In conclusion, the study by Blachier and colleagues offers a compelling new avenue for COVID-19 intervention by harnessing camelid antibodies to block ACE2-mediated viral entry. Their innovative approach not only impedes the virus effectively but protects the host without compromising essential physiological functions. As the world continues to grapple with SARS-CoV-2, this research marks a significant milestone towards durable and broad-spectrum antiviral therapeutics grounded in cutting-edge molecular engineering.

Subject of Research: Targeting the human ACE2 receptor to inhibit SARS-CoV-2 viral binding using a camelid-derived nanobody antibody, and evaluating its protective efficacy in vivo.

Article Title: Targeting ACE2 with a camelid antibody inhibits SARS-CoV-2 binding and has protective effects in vivo.

Article References:
Blachier, S., Vaney, MC., Conquet, L. et al. Targeting ACE2 with a camelid antibody inhibits SARS-CoV-2 binding and has protective effects in vivo. Nat Commun 16, 10268 (2025). https://doi.org/10.1038/s41467-025-65144-w

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41467-025-65144-w